Within the next decade, the size of the Alzheimer’s disease (AD) diagnostics and biomarkers market will overtake the market for currently available AD treatments, with an anticipated annual market value of at least $1 billion to $3 billion per year. Within the next five to 10 years, this market is expected to grow rapidly. Most companies developing AD diagnostics are focused on creating a product or system that facilitates the early detection of mild cognitive impairment (MCI), the precursor to AD. The ultimate size of the market depends on the number of modalities that are approved for use beyond the research setting where many of the biomarkers and radiotracers developed within the last several years are being used to facilitate measurement of key proteins that signal the presence of Alzheimer’s-like pathology. (SeeAlso see "Alzheimer's Dx: An Essential Piece of the Puzzle" - Medtech Insight, 1 February, 2011..)
Currently, the only way to diagnose AD is when a patient becomes symptomatic, or posthumously during an autopsy. If AD could be diagnosed before onset of symptoms, there would be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?